Gesynta Pharma

Gesynta Pharma is a clinical-stage biotech developing precision anti-inflammatory therapies by selectively inhibiting the mPGES-1 enzyme. Its lead asset, vipoglanstat, is in Phase 2 for endometriosis as a non-hormonal, non-opioid treatment, while a second candidate, GS-073, is poised for Phase 1 in chronic inflammatory pain. The company leverages foundational research from Karolinska Institutet and is led by a team with extensive drug development experience. Gesynta aims to address high unmet medical needs in chronic inflammatory conditions through its targeted mechanism.

Selective inhibition of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme, a key producer of the pro-inflammatory mediator PGE2, aiming for precise anti-inflammatory and analgesic effects with an improved safety profile compared to broader anti-inflammatories.

In endometriosis, Gesynta competes against hormonal therapies and emerging non-hormonal agents (e.g., neurokinin-1 antagonists, GnRH antagonists). In the broader chronic pain space, competition is intense, including NSAIDs, opioids, and novel biologic and small-molecule approaches. Gesynta's differentiation lies in its precise targeting of mPGES-1.